Vimta Labs Limited — PPTs, 17-07-2025: Investor Presentation

Here is the summary:

**1. Financial Highlights:**

Q1 FY26 saw robust financials: Total Income ₹99.3 Cr (+31.4% YoY), EBITDA ₹35.4 Cr (35.7% margin, +33.1% YoY), PAT ₹18.9 Cr (19.0% margin, +35.9% YoY). EPS ₹4.2. Significant CAPEX ₹24.12 Cr. Balance sheet shows low debt, healthy cash.

**2. Strategic Initiatives & Growth Drivers:**

Growth driven by capacity expansion, service innovations, market penetration. Favorable markets, rising demand for quality drugs, food, electronics, and cleaner environment drive strategy, boosted by biologics, vaccines, and "Make in India."

**3. Business Developments:**

VIMTA offers extensive contract research & testing across Drug Discovery & Development, Food & Agri, Electronics & Electricals, and Environment Testing. Ongoing investment in advanced labs & expert teams supports broad capabilities.

**4. Market Position & Competitive Advantage:**

VIMTA holds a strong market position: #1 in India for Pharma Analytical & Food Testing, leading in Electronics & Electricals. Strengths: unparalleled lab infrastructure, cutting-edge tech, strong quality culture, and long-term customer partnerships.

**5. Investor Implications:**

Highlights strong positive growth potential. Robust financials, strategic expansion, a leading position in high-growth segments, plus CAPEX reinvestment, suggest promising future demand.